Positions

Overview

  • Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Cutting Edge: Intracellular IFN-β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells.Journal of Immunology.  201:2203-2208. 2018
    2018 Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.Arthritis Care and Research.  70:1478-1487. 2018
    2017 A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus.Lupus.  26:1483-1490. 2017
    2017 Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.Arthritis and Rheumatology.  69:362-375. 2017
    2016 Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab.JCR: Journal of Clinical Rheumatology.  22:393-395. 2016
    2016 Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes.Clinical and Experimental Rheumatology.  34:953. 2016
    2016 A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.Journal of Immunology.  196:2492-2503. 2016
    2016 Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.Critical Care Medicine.  44:275-281. 2016
    2015 Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making.Arthritis Research.  17:367. 2015
    2015 Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique.Journal of Rheumatology.  42:1616-1623. 2015
    2015 Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome?Journal of Rheumatology.  42:1078-1080. 2015
    2015 Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.Arthritis and Rheumatology.  67:1848-1857. 2015
    2015 Vasculitis related to viral and other microbial agents.Best Practice and Research: Clinical Rheumatology.  29:226-243. 2015
    2014 Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.Journal of Rheumatology.  41:300-309. 2014
    2014 Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.Lupus Science & Medicine.  1:e000056. 2014
    2014 Macrophage Activation Syndrome Secondary to Human Monocytic EhrlichiosisIndian Journal of Hematology and Blood Transfusion.  30:145-147. 2014
    2013 Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations.PLoS Genetics.  9:e1003678. 2013
    2012 Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.Arthritis and Rheumatism.  64:4040-4047. 2012
    2012 Device for carrying blood samples at 37°C for cryoglobulin test.Clinical and Diagnostic Laboratory Immunology.  19:1555-1556. 2012
    2012 Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.Journal of Rheumatology.  39:1632-1640. 2012
    2012 Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.Arthritis and Rheumatism.  64:2328-2337. 2012
    2012 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care and Research.  64:625-639. 2012
    2012 Systemic lupus erythematosus: genomics, mechanisms, and therapies.Clinical and Developmental Immunology.  2012:926931. 2012
    2011 A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis and Rheumatism.  63:3918-3930. 2011
    2011 B lymphocytes are resistant to death receptor 5-induced apoptosis.Clinical Immunology.  139:21-31. 2011
    2010 Report of the American College of Rheumatology Pain Management Task Force.Arthritis Care and Research.  62:590-599. 2010
    2010 Rheumatic manifestations of systemic disease: sarcoidosis.Current Opinion in Rheumatology.  22:85-90. 2010
    2009 A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.Arthritis and Rheumatism.  61:1168-1178. 2009
    2009 Novel evidence-based systemic lupus erythematosus responder index.Arthritis and Rheumatism.  61:1143-1151. 2009
    2009 Increased expression of activation-induced cytidine deaminase is associated with anti-CCP and rheumatoid factor in rheumatoid arthritis.Scandinavian Journal of Immunology.  70:309-316. 2009
    2009 Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.Journal of Clinical Investigation.  119:1668-1677. 2009
    2008 Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.Arthritis and Rheumatism.  58:2453-2459. 2008
    2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis and Rheumatism.  59:762-784. 2008
    2008 Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.Arthritis Research.  10:R109. 2008
    2006 Ultrasound appearance of knuckle pads.Skeletal Radiology.  35:823-827. 2006
    2006 Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?Nature Clinical Practice Rheumatology.  2:240-241. 2006
    2006 Improving ambulatory prescribing safety with a handheld decision support system: a randomized controlled trial.Journal of the American Medical Informatics Association.  13:171-179. 2006
    2005 Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus.Arthritis and Rheumatism.  52:3943-3954. 2005
    2003 FcγRIIIb Allele-Sensitive Release of α-Defensins: Anti-Neutrophil Cytoplasmic Antibody-Induced Release of ChemotaxinsJournal of Immunology.  171:6090-6096. 2003
    2002 Normal radiographs in patients with persistent "hip pain"--value of magnetic resonance imaging.Journal of Rheumatology.  29:2463-2465. 2002
    2002 Immune function in patients with rheumatoid arthritis treated with etanercept.Clinical Immunology.  103:13-21. 2002
    2001 Treatment of lupus with corticosteroids.Lupus.  10:140-147. 2001
    2000 Renal failure: A risk factor for methotrexate toxicityArthritis and Rheumatism.  43:1185-1186. 2000
    1999 Update on sarcoidosis.Current Opinion in Rheumatology.  11:83-87. 1999
    1998 Ligation of CR1 attenuates Fc receptor-mediated myeloperoxidase release and HOCl production by neutrophils.Journal of Leukocyte Biology.  63:477-485. 1998
    1996 Acidic fibroblast growth factor (FGF-1) enhances huvec expression of ICAM-1 induced by IL-1βFederation proceedings.  10. 1996
    1996 Characterization of PepB, a group B streptococcal oligopeptidase.Infection and Immunity.  64:3401-3406. 1996
    1995 Rheumatoid synovial fibroblast adhesion to human articular cartilage. Enhancement by neutrophil proteases.Arthritis and Rheumatism.  38:1694-1700. 1995
    1995 Effects of tenidap on superoxide-generating enzymes. Non-competitive inhibition of xanthine oxidase.Biochemical Pharmacology.  50:811-814. 1995
    1995 Progressive joint destruction in a human immunodeficiency virus-infected patient with rheumatoid arthritis.Arthritis and Rheumatism.  38:1328-1332. 1995
    1995 Activation of human neutrophils by surface-associated IgA is associated with the release of activated collagenaseClinical immunology and immunopathology.  76:241-247. 1995
    1994 Determinants of neutrophil HOCl generation: ligand-dependent responses and the role of surface adhesion.Journal of Leukocyte Biology.  56:654-660. 1994
    1994 HOCl production by human neutrophils activated by surface-associated IgG: requirement for influx of extracellular calcium.Journal of Leukocyte Biology.  55:793-797. 1994
    1993 Fixation of C3 to IgG attenuates neutrophil HOCl generation and collagenase activation.Journal of Immunology.  151:949-958. 1993
    1993 Degradation of human articular cartilage by neutrophils in synovial fluid.Arthritis and Rheumatism.  36:51-58. 1993
    1992 Additive enhancement of neutrophil collagenase activity by HOCl and cathepsin G.Biochemical and Biophysical Research Communications.  184:560-567. 1992
    1992 Ligand dependent release of activated neutrophil collagenase--a role for surface bound IgG in the degradation of articular collagens.Matrix (Stuttgart, Germany). Supplement.  1:207-208. 1992
    1991 Tenidap, in contrast to several available nonsteroidal antiinflammatory drugs, potently inhibits the release of activated neutrophil collagenase.Arthritis and Rheumatism.  34:211-216. 1991
    1990 Lysis of fibrillar collagen by neutrophils in synovial fluid. A role for surface-bound immunoglobulins.Arthritis and Rheumatism.  33:1333-1339. 1990
    1990 Ligand-dependent release of active neutrophil collagenase.Arthritis and Rheumatism.  33:228-234. 1990
    1990 Letter to the editor (I)Arthritis and Rheumatism.  3:104-105. 1990
    1990 Letter to the editor (I)Arthritis and Rheumatism.  3:104-105. 1990
    1990 LettersArthritis and Rheumatism.  3:104-105. 1990
    1989 The replyAmerican Journal of Medicine.  86:634. 1989
    1989 Valvular heart disease in systemic lupus erythematosus.New England Journal of Medicine.  320:739-741. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Arthritis and Rheumatism.  2:70-74. 1989
    1989 Intraarticular corticosteroid injections: Should we rest the joints?Arthritis and Rheumatism.  2:70-74. 1989
    1988 Clinically significant valvular heart disease in systemic lupus erythematosus.American Journal of Medicine.  85:645-650. 1988
    1988 Cell surface receptors for kidney basement membranes.American Journal of Kidney Diseases.  12:78-83. 1988

    Chapter

    Year Title Altmetric
    2018 Management of autoimmune and inflammatory disorders in the setting of infection or immunodeficiency.  427-443. 2018

    Research Overview

  • Lupus Immunodeficiency associated autoimmunity Macrophage activation syndrome
  • Principal Investigator On

  • Private Grant  awarded by GlaxoSmithKline 2018 - 2021
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2017 - 2021
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2018 - 2020
  • Private Grant  awarded by Gilead Sciences 2018 - 2020
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2017 - 2019
  • Private Grant  awarded by Human Genome Sciences 2014 - 2019
  • Private Grant  awarded by Genentech 2017 - 2019
  • Private Grant  awarded by ASTRAZENECA PHARMACEUTICALS LP 2016 - 2019
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2019
  • Private Grant  awarded by ABLYNX NV 2016 - 2019
  • Private Grant  awarded by BENAROYA RESEARCH INSTITUTE 2015 - 2019
  • Private Grant  awarded by UCB BIOSCIENCES 2016 - 2018
  • Private Grant  awarded by MedImmune 2016 - 2018
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2018
  • Private Grant  awarded by MedImmune 2013 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2015 - 2018
  • Private Grant  awarded by EMD SERONO 2014 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2017 - 2018
  • Private Grant  awarded by SWEDISH ORPHAN BIOVITRUM AB 2016 - 2017
  • Private Grant  awarded by CELGENE CORPORATION 2014 - 2017
  • Private Grant  awarded by EMD SERONO 2014 - 2016
  • Private Grant  awarded by BIOGEN IDEC, INC. 2015 - 2016
  • Private Grant  awarded by Human Genome Sciences 2008 - 2016
  • Private Grant  awarded by Human Genome Sciences 2003 - 2016
  • Private Grant  awarded by IPSOS-INSIGHT, LLC 2014 - 2016
  • Private Grant  awarded by Human Genome Sciences 2012 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2012 - 2015
  • Private Grant  awarded by UCB, INC. 2011 - 2015
  • Private Grant  awarded by UCB PHARMA, INC. 2011 - 2015
  • Private Grant  awarded by MedImmune 2012 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2014 - 2015
  • Private Grant  awarded by GlaxoSmithKline 2014 - 2015
  • Private Grant  awarded by ELI LILLY AND COMPANY 2011 - 2014
  • Private Grant  awarded by DYNAVAX TECHNOLOGIES CORPORATION 2012 - 2014
  • A Randomized Double-Blind, Controlled, Phase II Multicenter Trial of CTLA4Ig (Abatacept) Plus Cyclophosphamide vs. Cyclophosphamide Alone in the Treatment of Lupus Nephritis - The Start Up Phase of Clinical Trial ITN #INT034AI  awarded by University of California, San Francisco 2008 - 2014
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2012 - 2013
  • Private Grant  awarded by Genentech 2009 - 2013
  • Private Grant  awarded by ANTHERA PHARMACEUTICALS, INC 2010 - 2013
  • Private Grant  awarded by CEPHALON, INC. 2011 - 2013
  • Private Grant  awarded by EMD SERONO 2008 - 2013
  • Private Grant  awarded by Human Genome Sciences 2008 - 2013
  • Private Grant  awarded by Centocor 2011 - 2013
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2013
  • Private Grant  awarded by MedImmune 2010 - 2012
  • Private Grant  awarded by UCB PHARMA, INC. 2008 - 2012
  • Private Grant  awarded by UCB PHARMA, INC. 2007 - 2012
  • Private Grant  awarded by CEPHALON, INC. 2010 - 2012
  • Effect of Vitamin D3 on the IFNa Signature in Patients with Systemic Lupus Erythmatosus - ACE  awarded by Duke University 2009 - 2012
  • Private Grant  awarded by Human Genome Sciences 2007 - 2011
  • Mapping Autoimmune Phenotypes in Multiplex Families  awarded by FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 2010 - 2011
  • Private Grant  awarded by Genentech 2007 - 2011
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2007 - 2011
  • Private Grant  awarded by CYPRESS BIOSCIENCE 2010 - 2011
  • Private Grant  awarded by Human Genome Sciences 2004 - 2010
  • Private Grant  awarded by NOVO NORDISK PHARMACEUTICALS, INC. 2009 - 2010
  • Teaching Activities

  • missing activity 2018
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2018) 2018
  • missing activity 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2018) 2018
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2018) 2018
  • missing activity 2018
  • missing activity 2018
  • missing activity 2018
  • missing activity 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 28-490 - RHEUMATOLOGY (Spring Term 2018) 2018
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Spring Term 2018) 2018
  • missing activity 2018
  • missing activity 2018
  • missing activity 2018
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • missing activity 2017
  • missing activity 2017
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • 28-490 - RHEUMATOLOGY (Fall Term 2017) 2017
  • missing activity 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • missing activity 2017
  • 28-490 - RHEUMATOLOGY (Spring Term 2017) 2017
  • missing activity 2017
  • missing activity 2017
  • missing activity 2017
  • missing activity 2016
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • 96-577 - IMMUNOLOGY/RHEUMATOLOGY MS3 ELECTIVE (Fall Term 2016) 2016
  • missing activity 2016
  • missing activity 2016
  • 28-490 - RHEUMATOLOGY (Fall Term 2016) 2016
  • missing activity 2016
  • missing activity 2016
  • missing activity 2016
  • 28-490 - RHEUMATOLOGY (Spring Term 2016) 2016
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2015) 2015
  • missing activity 2015
  • missing activity 2015
  • missing activity 2015
  • missing activity 2015
  • 28-490 - RHEUMATOLOGY (Spring Term 2015) 2015
  • missing activity 2015
  • 28-490 - RHEUMATOLOGY (Fall Term 2014) 2014
  • missing activity 2014
  • missing activity 2014
  • missing activity 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • missing activity 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Spring Term 2014) 2014
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2013) 2013
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2013) 2013
  • missing activity 2013
  • missing activity 2013
  • missing activity 2013
  • missing activity 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • missing activity 2013
  • 28-490 - RHEUMATOLOGY (Spring Term 2013) 2013
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • missing activity 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • missing activity 2012
  • missing activity 2012
  • 28-490 - RHEUMATOLOGY (Fall Term 2012) 2012
  • missing activity 2012
  • missing activity 2012
  • missing activity 2012
  • missing activity 2012
  • missing activity 2011
  • missing activity 2011
  • PCL1180 - MUSCULOSKELETAL & SKIN (Fall Term 2011) 2011
  • missing activity 2011
  • missing activity 2011
  • missing activity 2011
  • missing activity 2011
  • missing activity 2011
  • missing activity 2011
  • missing activity 2010
  • 28-490 - RHEUMATOLOGY (Fall Term 2010) 2010
  • 95-577 - RHEUMATOLOGY CLINICAL SELECTIVE (Fall Term 2010) 2010
  • missing activity 2010
  • missing activity 2010
  • missing activity 2010
  • missing activity 2009
  • missing activity 2009
  • missing activity 2009
  • missing activity 2009
  • missing activity 2009
  • 28-490 - RHEUMATOLOGY (Fall Term 2009) 2009
  • missing activity 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • missing activity 2009
  • 28-490 - RHEUMATOLOGY (Spring Term 2009) 2009
  • missing activity 2009
  • missing activity 2008
  • missing activity 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • missing activity 2008
  • 28-490 - RHEUMATOLOGY (Spring Term 2008) 2008
  • missing activity 2008
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • missing activity 2007
  • 28-490 - RHEUMATOLOGY (Fall Term 2007) 2007
  • missing activity 2007
  • missing activity 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • missing activity 2007
  • 28-490 - RHEUMATOLOGY (Spring Term 2007) 2007
  • Education And Training

  • Bachelor's Degree in General Studies, Duke University
  • Doctor of Medicine, Vanderbilt University
  • Full Name

  • W. Winn Chatham
  • Blazerid

  • wchatham